Mounjaro afeta o fígado? O que a tirzepatida faz ao seu fígado

Does Mounjaro harm the liver in people without liver disease?

The short answer is no, not in people with a normal liver. The Mounjaro UK Summary of Product Characteristics on the eMC does not list hepatotoxicity (drug-induced liver damage) as a known adverse effect, and liver enzyme elevations were not a pattern in SURMOUNT-1, the 72-week phase 3 trial involving thousands of adults with obesity.

That said, any medicine processed by the body involves the liver to some degree. Tirzepatide is cleared primarily through protein breakdown rather than through hepatic metabolism pathways, which is one reason the safety profile around liver toxicity looks clean. If you already have raised liver enzymes for another reason (alcohol, non-alcoholic fatty liver, medication) that is the kind of detail a prescriber needs to know before you start.

The NHS tirzepatide medicines page lists the recognised side effects; liver injury is not among them for people without pre-existing conditions. As with any prescription medicine, the full picture only emerges through a proper clinical assessment.

Can Mounjaro actually improve fatty liver disease?

This is where the liver story becomes genuinely interesting. Fatty liver disease (now more commonly called metabolic-associated steatotic liver disease (MASLD)) is closely tied to obesity and insulin resistance. Both are exactly what tirzepatide targets. As body weight falls during treatment, fat stored in the liver tends to fall with it.

Sub-analyses from the SURMOUNT programme showed reductions in liver fat alongside the headline weight-loss results, and this has attracted significant clinical interest. It is worth noting that semaglutide (Wegovy) received MHRA approval on 3 July 2026 specifically for MASH (metabolic-associated steatohepatitis, a more advanced form of fatty liver with fibrosis), a related GLP-1 mechanism. Tirzepatide research in this area is ongoing.

If fatty liver is part of your health picture, that is a strong reason to have a frank conversation with a prescriber about whether tirzepatide is appropriate for you, rather than a reason to avoid it. You can read more about our clinical team's approach on the clinical oversight page.

What about people with existing liver impairment?

The UK SmPC addresses this directly. For mild or moderate hepatic impairment, no dose adjustment is required and tirzepatide can be used, though with appropriate clinical oversight. Severe hepatic impairment is a different matter: the data here are limited, and the prescribing information advises caution. In practice, a prescriber will weigh the severity of the impairment, any co-existing medications that also burden the liver, and the overall benefit-risk balance.

This is exactly why Mounjaro is a prescription-only medicine, and if you are wondering whether you can access Mounjaro fara reteta or without going through a proper prescription process, the answer from a safety standpoint is that skipping a genuine clinical assessment means these nuances are simply skipped. That is not a small risk for someone with a liver condition.

If you are currently taking other medicines that affect the liver, such as a beta-blocker or similar long-term medication, it is worth raising those in your consultation too. Interactions are assessed case by case.

What should you tell your prescriber about your liver before starting?

Be upfront about any liver diagnosis, MASLD, MASH, hepatitis, cirrhosis, raised enzymes picked up at a recent blood test, or significant alcohol intake. Also mention any supplements marketed for liver health, since some (high-dose niacin, certain herbal products) can themselves affect liver enzymes and complicate the picture.

The nume consultation includes a full medical history review, carried out by a real GPhC-registered Independent Prescriber, not automated software. Orders placed before midday on a working day are reviewed the same day; if payday falls on a Thursday and you want to start that week, ordering in the morning keeps that timeline on track.

If tirzepatide is right for you, you can explore the treatment options and start a free consultation there. If you want broader context on how the drug works before deciding, the Mounjaro overview covers the mechanism, the SURMOUNT evidence and the UK licensing in full. For the oral alternative, the tirzepatide pillar page sets out how the two formulations compare.

One practical note: if you are waiting on liver blood results before starting, that is worth mentioning in your consultation, and our prescribers can walk you through exactly what each Mounjaro 2 mg starting dose involves and how the titration schedule works alongside any monitoring your liver situation may require. Many patients also ask how dosing progresses over time, and the Mounjaro 5 mg dose guidance page explains what to expect as you move through the escalation steps. Speak to our prescribers and they will tell you exactly what information they need.